tbuckley/cabot-search huggingface dataset:
The role of previous radical local treatment (RLT) on the outcome of immune checkpoint inhibitors (ICI) in patients (pts) with metastatic urothelial carcinoma (mUC).
Authors: Rafael Morales-Barrera, Natalia Vidal Casinello, Montserrat Domenech, Teresa Bonfill, Javier Puente, Mariona Figols, Julia Giner Joaquin, Macarena Gonzalez, Fernando Lozano, Hector Lopez, Isabel Galante, Richard Mast, Ester Serra Hernandez, Maria Eugenia Semidey, Cesar Serrano, Enrique Gallardo Diaz, Cristina Suarez Rodriguez, Xavier Maldonado, Juan Morote, Joan Carles
Journal: Journal of Clinical Oncology (2020)

496 Background: There is a growing interest in local treatment for metastatic solid tumors. Recently, retrospective studies have reported the potential benefit of RLT to primary bladder cancer in pts with metastatic disease. We tested the impact of previous RLT in pts with mUC treated with ICI. Methods: Data from pts with mUC treated with ICI collected between May 2013 and May 2019 using a multi-institutional database was evaluated. Stratification was made according to previous RLT with ICI versus no RLT with ICI. We defined RLT as radical surgery (RS) or ≥50 Gy of radiotherapy (RT) delivered to the bladder. The X 2 test was used to determine differences in rates. Overall survival (OS) between previous RLT plus ICI (group A) versus no RLT plus ICI (group B) generated using Kaplan-Meier method was compared by log-rank test. OS was calculated from the date of initiation of ICI to the date of death. Analyses were performed using SPSS v21. Results: A total of 115 pts with mUC were treated with ICI, 62 (53.9%) previously were treated with RS, 7(6.1%) RT and 46 (40%) no received RLT. ICI prescribed were atezolizumab (55.7%), pembrolizumab (16.5%), durvalumab (11.3%), durvalumab/tremelimumab (7.8%), nivolumab (5.2%) and avelumab (3.5%). The disease control rate (CR [6.9%] +PR [9.6%] +SD [14.1%]) was higher for pts with previous RLT compared to those pts who did not receive RLT (CR [3.2%] + PR [5.8%] + SD [6.4%](P=0.325). Median OS was 11.23 mo (95% CI; 6.02-16.44) and 7.95 mo (95%IC; 5.15-10.75) for group A and group B, respectively (P=0.481). Conclusions: This multicenter cohort suggests that previous RLT might play an impact for control disease in pts with mUC treated with ICI. Although this is hypothesis generating, the true value of this approach remains to be demonstrated in prospective studies.
GLUT1 expression in high-risk prostate cancer: Correlation with 18F-FDG-PET/CT and clinical outcome.
Authors: Frederic Pouliot, Salma Meizou, Cassandra Ringuette Goulet, Helene Hovington, Veronique Lefebvre, Etienne Lavallée, Michelle Bergeron, Hervé Brisson, Audrey Champagne, Bertrand Neveu, Didier Lacombe, Jean-Mathieu Beauregard, François-Alexandre Buteau, Julie Riopel
Journal: Journal of Clinical Oncology (2020)

291 Background: Tumour FDG-uptake is of prognostic value in high-risk and metastatic prostate cancer (PCa). The aim of this study is to investigate the underlying glucose metabolism mechanisms of 18F-FDG-uptake on PET/CT imaging in PCa. Methods: Retrospective analysis was conducted for 94 patients diagnosed with a Gleason sum ≥8 at biopsy who underwent 18F-FDG-PET/CT imaging before radical prostatectomy. GLUT1, GLUT12 and HK2 expression were blindly scored after immunohistochemistry on radical prostatectomy specimens by 3 pathologists. 18F-FDG-uptake in primary lesion was measured by a blinded reader using maximum standardized uptake value (SUVmax). Correlations between GLUT1, GLUT12 and HK2 and SUVmax were assessed using Spearman’s rank correlation test. Survival probabilities were based on the Kaplan-Meier method. Results: With a median follow-up of 4.5 years, 56% (n=53) of patients had biochemical recurrence, 7% (n=7) progressed to castration-resistant PCa (CRPC) disease, 13% (n=12) developed metastasis and 6% (n=6) died. Correlation was found between GLUT1 expression and SUVmax level (r=0.2512, p=0.0182). In addition, SUVmax was significantly higher in tumours with high GLUT1 expression (n=17, 5.74±1.67) than tumours with low GLUT1 expression (n=71, 2.68±0.31, P=0.0037). Also, contrary to GLUT12 and HEX2 expression, a significant association was found between GLUT-1 expression levels and SUVmax index (p=0.004), lymph node status (p=0.046), volume of cancer (P=0.013), CRPC-free survival (p=0.02) and metastasis-free survival (p=0.04). Conclusions: GLUT1 expression in PCa tumours correlates with 18F-FDG-uptake and poor prognostic factors. These results suggest that this transporter is involved in the molecular mechanism of 18F-FDG-uptake in high-risk PCa and raise interest in targeting metabolic dependencies of PCa cells as a selective anticancer strategy.
Clinical Features, Inducers and Treatment of Anaphylaxis in Latin America and Spain
Authors: Edgardo Jares, Maximiliano Gomez, Victoria Cardona, Mario Sanchez-Borges, Alberto Lavrut, Alicia De Falco, Maria Souza, Maria Diaz, Juan Ivancevich, Nelson Rosario, Mara Felix, Blanca Morfin-Maciel, Ivan Cherrez Ojeda, Pablo Slullitel, Ivan Tinoco Moran, Pedro Piraino, Perla Alcaraz Duarte, Jonathan Bernstein, Iris Ale, Pierre Chávez Vereau
Journal: Journal of Allergy and Clinical Immunology (2020)
Food Protein Induced Enterocolitis Syndrome (FPIES) In Adults Is Not Exceptional
Authors: Jimena Crespo Quirós, Maria Esperanza Perez Pallise, Filip Skrabski, Francisco Castro Martinez, Cristina Morales Cabeza, Laura Palomino-Lozano, Sonsoles Infante
Journal: Journal of Allergy and Clinical Immunology (2020)
Abstract 15687: Iron Deficiency Reduces Myocardial Tolerance to Ischemia/Reperfusion Injury by Inhibiting the eNOS/sGC/PKG Pathway
Authors: Javier Inserte, José A Barrabés, Natalia Jordà, David Aluja, Mercè Bonastre, David Garcia-Dorado
Journal: Circulation (2018)

Introduction: The relevance of iron deficiency (ID) in the setting of acute coronary syndrome (ACS) remains unclear. Evidence suggests that ID may affect the cardioprotective pathway endothelial ni...
Evidence Still Lacking for Recommendation of Screening for Cognitive Impairment in Older Adults
Authors: Carol Brayne
Journal: JAMA Internal Medicine (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Abstract 10929: Effects of Ivabradine on Residual Myocardial Ischemia After PCI Evaluated by Stress Echocardiography
Authors: Fabio Infusino, Simone Calcagno, Olga Dettori, Pasqualina Bruno, Massimo Mancone, Gennaro Sardella, Paolo Severino, Mariateresa Pucci, Viviana Maestrini, Natale Marco Martello, Nicolò Salvi, Francesco Fedele
Journal: Circulation (2018)

Introduction: Residual angina after PCI is a frequently-occuring condition. Ivabradine improves symptoms but its role in patients without left-ventricular systolic dysfunction is still unclear. Hyp...
The relationship between 5-Fluorouracil(5-FU) sensitivity and single nucleotide polymorphisms(SNPs) of orotate phosphoribosyl transferase(OPRT) gene in cororectal cancer
Authors: Masayuki Kitajima, Naohito Takita, Masaki Hata, Tsutomu Maeda, Kazuhiro Sakamoto, Toshiki Kamano, Takumi Ochiai
Journal: Cancer Research (2005)

3297  Orotate phosphoribosyl transferase(OPRT) is one of the critical enzyme involved in the onset of 5-Fluorouracil(5-FU) effects. Recently , various molecular biological analyses concerning human genes have been conducted , Of which single nucleotide polymorphisms(SNPs) are widely used to predict pharmacologic and adverse effects in genomic drug discovery. In this report, we investigated the relationship between 5-FU sensitivity and SNPs of OPRTgene in cororectal cancer. The subject were 32 patients(21 male patients, 11 female patients, mean age;64.0) with colorectal cancer who underwent surgical resection in our hospital between Descember,2003 and July,2004. HIstologic gradeswere as follows: 13cases of well-differentiated adenocarcinoma, 16cases of moderately -differentiated adenocarcinoma, 1case of poorly -differentiated adenocarcinoma, 2 cases of mucoid carcinoma. Polymorphisms(638G/C,1050T/A,1336A/G), which were speculated to affect OPRT enzyme activity, were analyzed using an invader method. In addition, Using a collagen gel droplet embedded culture drug sensitivity test (exposure condition; 10μg/ml×3hrs, 0.2μg/ml×24hrs, 1.0μg/ml× 24hrs, 10μg/ml×24hrs, 0.2μg/ml×120hrs, 1.0μg/ml×120hrs), Inhibition rates(%IR) on colorectal cancer growth were determined under each exposure condition, and 5-FU sensitivities were compared among each polymorphisms (wild-, homo-, and hetero-type). No significant difference under 6 exposure conditions was found among strains with each polymorphism(wild-, homo-, and hetero-type).   We concluded that these SNPs in OPRT gene had little effect on 5-FU sensitivity.
Development of 3-mercaptopropyltrimethoxysilane (MPTS)-modified bone marrow mononuclear cell membrane chromatography for screening anti-osteoporosis components from Scutellariae Radix
Authors: Yanqiu Gu, Xiao Chen, Yao Wang, Yue Liu, Leyi Zheng, Xiaoqun Li, Rong Wang, Shaozhan Wang, Shengnan Li, Yifeng Chai, Jiacan Su, Yongfang Yuan, Xiaofei Chen
Journal: Acta Pharmaceutica Sinica B (2020)

Osteoporosis is a bone metabolic disease caused by the imbalance between osteoblasts and osteoclasts due to excess osteoclastogenesis, manifesting in the decrease of bone density and bone strength. Scutellariae Radix shows good anti-osteoporosis activity, but the effective component is still unclear. Cell membrane chromatography (CMC) is a biological affinity chromatography with membrane immobilized on a silica carrier as the stationary phase. It can realize a dynamical simulation of interactions between drugs and receptors on cell membrane, which is suitable for screening active compounds from complex systems. In this study, the components of Scutellariae Radix with potential anti-osteoporosis activity through inhibiting the differentiation from bone marrow mononuclear cells (BMMCs) to osteoclast were screened by a BMMC/CMC analytical system. Firstly, a new 3-mercaptopropyltrimethoxysilane (MPTS)-modified BMMC/CMC stationary phase was developed to realize covalent binding with cell membrane fractions. By investigating the retention time (tR) of the positive drug, the life span of the MPTS-modified CMC columns was significantly improved from 3 to 12 days. Secondly, 6 components of Scutellariae Radix were screened to show affinity to membrane receptors on BMMCs by a two-dimensional BMMC/CMC-TOFMS analytical system. Among them, tectochrysin demonstrated the best anti-osteoporosis effect in vitro, which has never been reported. We found that tectochrysin could inhibit the differentiation of BMMCs into osteoclasts induced by receptor activator of nuclear factor-κΒ ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) in a concentration-dependent manner in vitro. In vivo, it significantly reduced the loss of bone trabeculae in ovariectomized mice, and decreased the level of C-terminal cross-linking telopeptides of type 1 collagen (CTX-1), tartrate-resistant acid phosphatase 5b (TRAP-5b), interleukin 6 (IL-6) in serum. In conclusion, tectochrysin serves as a potential candidate in the treatment of osteoporosis. The proposed two-dimensional MPTS-modified BMMC/CMC-TOFMS analytical system shows the advantages of long-life span and fast recognition ability, which is very suitable for infrequent cell lines.
Addiction psychiatry could be wiped out in a decade without urgent government funding, college warns
Authors: Abi Rimmer
Journal: BMJ (2020)

Falling trainee numbers mean that addiction psychiatry could be wiped out in the next 10 years unless urgent measures are taken, the Royal College of Psychiatrists has warned.

A report on the state of training in addiction psychiatry,1 published by the college, revealed that the number of higher training posts across England had …
Medicine Is Not a Subway Ride
Authors: Shan Ali
Journal: JAMA Oncology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.
Authors: Marit Vermunt, Debbie Robbrecht, Lot Devriese, Julie Janssen, Marianne Keessen, Ferry Eskens, Jos H. Beijnen, Niven Mehra, Andre M. Bergman
Journal: Journal of Clinical Oncology (2020)

79 Background: ModraDoc006 is a novel formulation of docetaxel and to enhance bioavailability, this tablet is co-administered with ritonavir (r), an inhibitor of cytochrome p450 3A4 and P-glycoprotein. The safety, anti-tumor activity and pharmacokinetics (PK) of ModraDoc006/r were investigated by dose-escalation in patients with mCRPC, to propose a recommended phase 2 dose (RP2D). Methods: Progressive mCRPC patients, who were treatment naïve or previously treated with either abiraterone or enzalutamide, received a maximum of 30 weekly cycles of ModraDoc006/r in a bi-daily once weekly (BIDW) schedule. Plasma docetaxel concentrations were determined at the first 2 cycles up to 48h after intake of ModraDoc006/r. Adverse events were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Serum Prostate Specific Antigen (PSA) levels were assessed every 6 weeks. Results: 23 patients were included, of whom 20 were evaluable for safety and PK. In 5 patients, the initial 30-20/100-100 dose was explored, with observation of one dose limiting toxicity (DLT) (grade 3 alanine aminotransferase increase). The next dose level of 30-20/200-200 resulted in 2 DLTs in 6 patients (grade 3 diarrhea and mucositis). Subsequently, two intermediate dose levels: 30-20/200-100 and 20-20/200-100 were explored in 6 and 3 patients. At the 30-20/200-100 dose, an adequate docetaxel exposure was achieved and 1 DLT (grade 3 diarrhea) was observed, with no DLTs at the 20-20/200-100 dose. Common treatment-related AEs (occurring in &gt; 30% of all patients) were diarrhea, nausea, vomiting, anorexia and fatigue. Five patients completed the maximum of 30 weekly treatments. In 10 patients, evaluable for anti-tumor activity after treatment with ≥9 cycles, 4 confirmed and 2 non-confirmed PSA responses ( &gt; 50% decrease) were observed. Conclusions: The RP2D of BIDW ModraDoc006/r in mCRPC was established as 30-20/200-100 mg. These results are encouraging for further development of ModraDoc006/r as a convenient, safe and effective alternative to IV docetaxel for mCRPC patients. A phase 2b study is currently being conducted. Clinical trial information: NCT03136640.
Type II Epithelial RhoA Protects against Allergic Airway inflammation and the Formation of Inducible Bronchus-Associated Lymphoid Tissue (iBALT)
Authors: Yan Zhang, Wei Tu, Danh Do, Xia Ke, Chengping Hu, Yi Zheng, Peisong Gao
Journal: Journal of Allergy and Clinical Immunology (2020)
Assessment of a 2-Step Urine Culture Ordering Process for Detecting Asymptomatic Bacteruria Among Hospitalized Patients
Authors: Maureen T. Taylor, Janine McCready, Thomas Havey, Sahejpreet Kaur, Jeff Powis
Journal: JAMA Network Open (2020)

This quality improvement study evaluates the association of a 2-step urine culture ordering process with the number of urine cultures processed each month and the detection of asymptomatic bacteruria and candiduria among patients hospitalized in an acute care setting.
Abstract 20411: Identifying the Predictive Factors of Cardiac Resynchronization Therapy Response: A Comparative Study Using Machine Learning and Logistic Regression Analysis
Authors: Haipeng Tang, Ningchao Tao, Chaoyang Zhang, Jiangang Zou, Weihua Zhou
Journal: Circulation (2017)

Introduction: Around 30-40% patients who received cardiac resynchronization therapy (CRT) didn’t respond to CRT. Left-ventricular myocardial viability and mechanical dyssynchrony measured from gate...
Cross‐sectional study identifies lower risk of <i>Staphylococcus aureus</i> nasal colonization in Danish blood donors with hidradenitis suppurativa symptoms
Authors: K.M. Dinh, L.T. Erikstrup, R.K. Andersen, P.S. Andersen, S. Mikkelsen, B.D. Kjerulff, K.S. Burgdorf, T.F. Hansen, K.R. Nielsen, H. Hjalgrim, G.B. Jemec, H. Ullum, C. Erikstrup, O.B. Pedersen
Journal: British Journal of Dermatology (2020)
Primary malignant melanoma of the female urethra: Twenty years of surgical and medical management at a tertiary referral center.
Authors: Paige Nichols, Tanner Miest, Brian D. Montgomery, Vidit Sharma, Deborah Lightner, Derek Lomas
Journal: Journal of Clinical Oncology (2020)

430 Background: Malignant melanoma of the female urethra accounts for less than 1% of all melanoma and less than 4% of urethral cancer. Due to limited data regarding management and outcomes of this condition, we evaluated the management and outcomes of urethral melanoma in females over the last 20 years at our institution. Methods: Patients were identified via retrospective review of the medical record. Those with metastatic disease at initial diagnosis were excluded. We evaluated primary and adjuvant treatments, disease recurrence and overall survival. Results: Fifteen women (median age 71, range 55, 82) were identified. Majority of masses involved the distal urethra (86.6%). All patients underwent primary surgical resection (60.0% partial urethrectomy, 40.0% radical urethrectomy). Disease recurrence and metastatic spread occurred in 73.3% (median 7 months, IQR 4, 12) and 60% (median 6 months, IQR 3, 9) of patients, respectively. 90.9% of patients with recurrence received adjuvant therapy: 5 chemotherapy and radiation, 4 chemotherapy only, 1 anterior exenteration. Of the 9 patients undergoing chemotherapy, treatment regimens were varied and included checkpoint inhibitors (2/9), platinum-based chemotherapy (3/9), tyrosine kinase inhibitors (2/9), taxels (2/9), and alkylating agents (1/9). Median overall survival was 27 months (IQR 7.5, 57.5). Conclusions: Malignant melanoma of the urethra is locally aggressive with a high likelihood of recurrence and metastases resulting in poor long-term survival. Despite high recurrence rates, our data highlight the lack of consensus adjuvant treatment regimens. Future research is required to identify neoadjuvant, combination, and adjuvant treatment approaches to improve disease outcomes.
Survey of ADT-induced estrogen deficiency-related side effects in a contemporary cohort of men with advanced prostate cancer.
Authors: Robert H. Getzenberg, Mark C. Scholz, Alexandra Scholz, Mitchell S. Steiner
Journal: Journal of Clinical Oncology (2020)

235 Background: Androgen Deprivation Therapy (ADT) is a mainstay in the treatment of advanced prostate cancer. ADT-induced estrogen deficiency related side effects may cause men to delay, pause, or discontinue ADT, increases morbidity and mortality, and can significantly impact quality of life. ADT-induced effects include hot flashes, bone loss and fractures, fatigue, decreased libido, and metabolic and lipid changes. Currently there are no FDA approved treatments for ADT-induced hot flashes in men with advanced prostate cancer. In this study, a survey was conducted on the impact of hot flashes, one of the hallmark ADT-induced estrogen deficiency effects, in a contemporary cohort. Methods: During the period of August/September 2019, 212 men with advanced prostate cancer on ADT participated in a digital survey conducted by the Prostate Cancer Research Institute (PCRI) focused on the frequency, severity and impact of their hot flashes. The men were at least 50 years of age with 61% being 70 or older. ADT types included LUPRON Ò (64%), ELIGARD Ò (12%), ZOLADEX Ò (7%) and other forms of hormonal therapy (17%). Results: Of the 212 men surveyed, 99% reported hot flashes with 80% indicating that they experience clinically significant, moderate to severe hot flashes. 77% of men reported that the number of hot flashes stayed the same or increased during their hormonal therapy. 37% of the men experienced more than 5 hot flashes per day and 23% indicated that they felt embarrassed about their hot flashes. Only 51% had either researched how to address their hot flashes or discussed them with their physician. Importantly, 16% considered halting ADT as a result of their hot flashes. Conclusions: This contemporary survey underscores the significant unmet medical need to treat moderate to severe hot flashes which occurred in 80% of the men studied. As about half of the men have not discussed their symptoms with a physician either because of embarrassment or lack of treatment options, the number of men with moderate to severe hot flashes appears to be greatly under-reported. As men on ADT are living longer with prostate cancer, finding an effective and safe treatment for debilitating hot flashes must be a priority.
Effects and cost of different strategies to eliminate hepatitis C virus transmission in Pakistan: a modelling analysis
Authors: Aaron G Lim, Josephine G Walker, Nyashadzaishe Mafirakureva, Gul Ghuttai Khalid, Huma Qureshi, Hassan Mahmood, Adam Trickey, Hannah Fraser, Khawar Aslam, Gregoire Falq, Camille Fortas, Hassaan Zahid, Ammara Naveed, Rosa Auat, Quaid Saeed, Charlotte F Davies, Christinah Mukandavire, Nancy Glass, David Maman, Natasha K Martin, Matthew Hickman, Margaret T May, Saeed Hamid, Anne Loarec, Francisco Averhoff, Peter Vickerman
Journal: The Lancet Global Health (2020)

The WHO elimination strategy for hepatitis C virus advocates scaling up screening and treatment to reduce global hepatitis C incidence by 80% by 2030, but little is known about how this reduction could be achieved and the costs of doing so. We aimed to evaluate the effects and cost of different strategies to scale up screening and treatment of hepatitis C in Pakistan and determine what is required to meet WHO elimination targets for incidence.